NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 66 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $113,440 | +18.6% | 136,675 | 0.0% | 0.00% | – |
| Q1 2023 | $95,673 | +37.5% | 136,675 | 0.0% | 0.00% | – |
| Q4 2022 | $69,568 | -94.7% | 136,675 | -93.4% | 0.00% | -100.0% |
| Q3 2022 | $1,321,000 | -10.8% | 2,064,222 | +43.6% | 0.01% | -16.7% |
| Q2 2022 | $1,481,000 | -35.7% | 1,437,417 | +17.3% | 0.01% | -33.3% |
| Q1 2022 | $2,303,000 | -52.7% | 1,225,000 | +21.2% | 0.01% | -52.6% |
| Q4 2021 | $4,872,000 | -32.6% | 1,010,790 | +1.1% | 0.02% | -40.6% |
| Q3 2021 | $7,230,000 | -11.3% | 1,000,000 | +13.2% | 0.03% | -13.5% |
| Q2 2021 | $8,151,000 | -49.4% | 883,102 | -32.5% | 0.04% | -50.7% |
| Q1 2021 | $16,109,000 | -4.5% | 1,308,600 | +9.4% | 0.08% | -8.5% |
| Q4 2020 | $16,860,000 | +40.5% | 1,195,725 | +19.6% | 0.08% | +34.4% |
| Q3 2020 | $11,996,000 | +47.2% | 999,694 | +103.6% | 0.06% | +15.1% |
| Q2 2020 | $8,151,000 | +19.1% | 490,996 | -18.3% | 0.05% | -5.4% |
| Q1 2020 | $6,842,000 | +338.0% | 601,193 | +374.2% | 0.06% | +600.0% |
| Q4 2019 | $1,562,000 | – | 126,782 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,047,300 | $5,048,000 | 1.07% |
| ACT CAPITAL MANAGEMENT, LLC | 212,500 | $1,024,000 | 0.74% |
| Redmile Group, LLC | 3,490,835 | $16,826,000 | 0.38% |
| Kynam Capital Management, LP | 147,000 | $709,000 | 0.38% |
| EcoR1 Capital, LLC | 860,619 | $4,148,000 | 0.13% |
| Baker Brothers Advisors | 3,821,740 | $18,421,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 130,899 | $631,000 | 0.08% |
| Sio Capital Management, LLC | 38,312 | $185,000 | 0.06% |
| Highland Private Wealth Management | 46,999 | $227,000 | 0.03% |
| XTX Topco Ltd | 10,018 | $48,000 | 0.03% |